Quest Diagnostics to Offer Cytyc’s ThinPrep® Pap Test™

June 19, 1997

BOXBOROUGH, MA, June 19, 1997 -- Cytyc Corporation (NASDAQ:CYTC) today announced a multi-year agreement with Quest Diagnostics Incorporated (NYSE:DGX), one of the nation's largest providers of Pap smear testing, to offer Cytyc's ThinPrep® Pap Test™ as a new cervical cancer screening technology. Quest Diagnostics will introduce the ThinPrep Pap Test progressively throughout its network of laboratories around the country beginning next month. Quest Diagnostics will continue to offer the conventional Pap smear, which has been recognized as a valuable screening test responsible for the early detection of cervical cancer and the reduction of mortality rate associated with this disease.

The ThinPrep Pap Test uses a new proprietary technology that enhances the collection and presentation of cervical samples and improves slide preparation. The U.S. Food and Drug Administration approved the ThinPrep system for use in screening for cervical cancer in May 1996. In November 1996, the FDA approved expanded claims that the ThinPrep Pap Test is significantly more effective than the conventional Pap smear for the detection of low-grade and more severe lesions in a variety of patient populations and significantly improves specimen quality.

"Quest Diagnostics is committed to improving women's health by providing high quality cervical cancer screening, including the conventional Pap smear and the ThinPrep Pap Test, at an appropriate price," said Gregory Critchfield, MD, Senior Vice President and Chief Medical and Science Officer for Quest Diagnostics. "Women and their doctors have a choice in selecting the cervical screening method that best meets their need."

"One challenge we face in introducing a new technology is reimbursement by third party payors," said Dr. Critchfield. "In view of the value this new technology brings and the additional costs, we will be working with Cytyc to negotiate with third party payors for coverage of this new test for their members at an appropriate price."

"We are delighted with Quest Diagnostics' decision to provide the ThinPrep Pap Test," said Patrick J. Sullivan, President and Chief Executive Officer, Cytyc Corporation. "Quest Diagnostics has a well-deserved reputation for quality and innovation in clinical diagnostic services which we believe will be further enhanced by their decision to offer the ThinPrep Pap Test."

Cytyc Corporation develops, manufactures, and markets the ThinPrep System for medical diagnostic applications. The ThinPrep System consists of the ThinPrep 2000 Processor and related reagents, filters, and other supplies. The ThinPrep Pap Test was cleared by the U.S. Food and Drug Administration in May of 1996, as a replacement for the conventional Pap smear preparation. Currently over 400 laboratories in the United States utilize the ThinPrep 2000 for use in the diagnosis of cancers including cancers of the cervix, lung, bladder, and gastrointestinal tract and in preparation of fine needle aspiration of thyroid and breast.

Quest Diagnostics Incorporated is one of the world's leading providers of diagnostic testing, services and information, with regional laboratories located throughout the United States. The wide variety of tests performed on human tissue and fluids help doctors and hospitals diagnose, treat and monitor diseases and disease states. In addition, Quest Diagnostics' Nichols Institute conducts research, produces test kits and instruments, and specializes in esoteric testing using genetic screening and other advanced technologies. Formerly known as Corning Clinical Laboratories Inc., Quest Diagnostics was spun off to Corning Incorporated stockholders in a tax-free distribution of shares on December 31, 1996.

Cytyc® and ThinPrep® are registered trademarks and ThinPrep Pap Test™ is a trademark of Cytyc Corporation. Quest Diagnostics and its logo are trade/servicemarks and Nichols Institute is a servicemark of Quest Diagnostics Incorporated.

FOR CYTYC INVESTORS:

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding management's plans and objectives for future operations, product plans and performance, potential savings to the health care system, management's assessment of market factors, as well as statements regarding the strategy and plans of the Company, constitute forward-looking statements which involve risks and uncertainties, including, without limitation, risks associated with the Company's dependence on a single product, uncertainty of market acceptance and additional cost, dependence on third-party reimbursement, limited marketing and sales experience, and limited number of customers and lengthy sales cycle, as well as risks of downturns in economic conditions generally, and in the health care industry specifically, risks associated with competition and competitive pricing pressures, and other risks detailed in the Company's filings with the Securities and Exchange Commission, and in its 1996 Form 10-K filed with the Commission.